Prospective Evaluation of Lifestyle-modifying Interventions on Disease Parameters, Inflammatory and Metabolic Processes in Low-risk MDS Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 36
- 主要终点
- Hematological improvement
研究概览
简要总结
Myelodysplastic syndromes (MDS) are acquired clonal stem cell diseases characterized by hematopoietic cell dysplasia, cytopenia, and the risk of progression to acute myeloid leukemia. In addition to clonal changes in the hematopoietic stem and progenitor cells itself, growing evidence suggests that inflammatory and metabolic changes in the bone marrow microenvironment play an important role in disease development and maintenance of the malignant clone. The positive impact of dietary interventions (e.g. fasting) and physical activity on inflammation and metabolic parameters could be shown in various benign inflammatory disease entities (e.g. atherosclerosis, chronic renal insufficiency, cystic fibrosis etc.).
The aim of this study is to describe the hematological, metabolic, inflammatory, and microbiological changes after combined lifestyle-modifying interventions (outpatient physiotherapy and fasting mimicking diet (FMD) in patients with low-risk MDS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years of age
- •Cytomorphologically confirmed MDS or MDS/MPN according to WHO criteria (incl. MDS-RARS-T, CMML)
- •IPSS-R very low, low, or intermediate
- •Hemoglobin <11 g/dL (6.8 mmol/l)
- •Non-transfusion dependent (NTD) per IWG 2018 criteria (≤2 blood transfusions within 16 weeks prior to inclusion in the study)
- •Body mass index (BMI) ≥ 20 kg/m2
- •Written informed consent of the subject after clarification
排除标准
- •MDS IPSS-R high or very high
- •History of HSCT
- •MDS-specific drug therapy (including erythropoietin, erythropoiesis-modulating agents, lenalidomide, iron chelation, hypomethylating agents) ongoing or planned in the next 6 months
- •Diabetes mellitus requiring therapy or any other known metabolic disease
- •Application of systemic cortisone-containing drugs
- •Known psychiatric eating disorder (e.g. anorexia nervosa, bulimia)
- •Physical inability to follow the physical and/or nutritive interventions
- •simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion)
- •addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
- •pregnant or breastfeeding women
- •indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance)
结局指标
主要结局
Hematological improvement
时间窗: 24 weeks
Hemoglobin level at the EOT visit, g/dL
次要结局
- Patients' adherence to therapy as an expression of the relevance of the lifestyle-modifying interventions in everyday life(6 months)
- Evaluation of a priori metabolic parameters of MDS patients after combined physiotherapeutic and nutritive interventions(6 months)
- Evaluation of a priori inflammatory parameters of MDS patients after combined physiotherapeutic and nutritive interventions(6 months)
- Impact on fatigue(6 months)
- Impact on quality of life(6 months)